secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2024-12-13T23:59:59+00:00
Accession:  0001193125-24-278529
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Benitec appoints Sophie Mukadam as COO, Megan Boston as CFO; grants stock options to executives
--------------------------------------------------------------------------------

- Sophie Mukadam appointed COO effective Jan 1, 2025; base salary $500K, target bonus 40%.
- Megan Boston confirmed as Secretary and CFO effective Jan 1, 2025; continues as principal financial/accounting officer.
- CEO Jerel Banks granted options for 2.31M shares at $12.18, vesting quarterly over four years.
- CFO Megan Boston granted options for 720K shares at same price/vesting schedule.
- Base salaries increased: CEO to $667K, CFO to $415K, effective Jan 1, 2025; target bonuses 55% and 40%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524278529/0001193125-24-278529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524278529/d853112d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-278529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer